Form 8-K - Current report:
SEC Accession No. 0001104659-20-102224
Filing Date
2020-09-03
Accepted
2020-09-03 16:05:46
Documents
14
Period of Report
2020-09-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2030135d1_8k.htm   iXBRL 8-K 30371
2 EXHIBIT 10.1 tm2030135d1_ex10-1.htm EX-10.1 97323
6 GRAPHIC image_001.gif GRAPHIC 2462
  Complete submission text file 0001104659-20-102224.txt   332683

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bcli-20200902.xsd EX-101.SCH 3207
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20200902_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20200902_pre.xml EX-101.PRE 22724
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2030135d1_8k_htm.xml XML 3617
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 201159327
SIC: 2836 Biological Products, (No Diagnostic Substances)